

REMARKS/ARGUMENTS

In the specification, the paragraphs 2 on page 19 through 2, page 22 have been amended to reflect the correct names for the structures shown. Since the structures are accurately drawn, no new matter is disclosed

Claims 1-71 were pending in the application. Claims 1-71 were subject to a requirement for restriction. The restriction was as follows:

- I. Claims 1-2, 11-71, drawn to method of treating or preventing inflammation associated disorders, wherein the etiologies of the inflammation are defined in claim 2, classified in class 514, subclass 169+.
- II. Claims 1, 3-71, drawn to method of treating or preventing inflammation associated disorders, wherein the disorder is cardiovascular disorders, classified in class 514, subclass 169+.
- III. Claims 1, 8-71, drawn to method of treating or preventing inflammation associated disorders, wherein the disorders are other than those defined in groups I and II, classified in class 514, subclass 169+.

Applicants elect group II without traverse.

Claims 1-71 have been canceled without prejudice to their presentation in one or more continuing applications directed to the subject matter thereof.

New claims 72-96 are pending in the present application. New claims 72-96 are directed to a method of treating or preventing inflammation related cardiovascular disorders by administering an effective amount of an epoxy-steroidal aldosterone receptor antagonist. It is believed that new claims 72-96 are consonant with the above election of Group II.


Applicants further elect myocardial infarction as the species of cardiovascular disorder, and eplerenone as the species of epoxy-steroidal aldosterone receptor antagonist for purposes of examination. New claims 74 and 76 correspond to these elected specie.

New claim 74 is drawn to a method of treating myocardial infarction by administering an epoxy steroidal aldosterone receptor antagonist. New claims 76 and 92-96 are directed to treating or preventing an inflammation related cardiovascular disorder by administering an effective amount of eplerenone.

If a telephonic interview with Applicant's representative would aid in the prosecution of this application, the Examiner is cordially invited to contact Applicant's representative at the below listed number.

Respectfully submitted,

Pharmacia Corporation
Corporate Patent Department
P.O. Box 1027
Chesterfield, Missouri 63006



Philip B. Polster II
Reg. No. 43,864
(314) 274-9094
(314) 274-9095 (facsimile)